Duchesne G - Search Results

1

Radiation dose escalation or longer androgen suppression for locally advanced prostate cancer? Data from the TROG 03.04 RADAR trial.

Denham JW, Steigler A, Joseph D, Lamb DS, Spry NA, Duchesne G, Atkinson C, Matthews J, Turner S, Kenny L, Tai KH, Gogna NK, Gill S, Tan H, Kearvell R, Murray J, Ebert M, Haworth A, Kennedy A, Delahunt B, Oldmeadow C, Holliday EG, Attia J. Denham JW, et al. Among authors: duchesne g. Radiother Oncol. 2015 Jun;115(3):301-7. doi: 10.1016/j.radonc.2015.05.016. Epub 2015 Jun 10. Radiother Oncol. 2015. PMID: 26072289 Clinical Trial.

2

Identification of intermediate-risk prostate cancer patients treated with radiotherapy suitable for neoadjuvant hormone studies.

Duchesne GM, Bloomfield D, Wall P. Duchesne GM, et al. Radiother Oncol. 1996 Jan;38(1):7-12. doi: 10.1016/0167-8140(95)01645-7. Radiother Oncol. 1996. PMID: 8850420

3

Radiation for prostate cancer.

Duchesne GM. Duchesne GM. Lancet Oncol. 2001 Feb;2(2):73-81. doi: 10.1016/S1470-2045(00)00223-0. Lancet Oncol. 2001. PMID: 11905798 Review.

4

Dose distribution and morbidity after high dose rate brachytherapy for prostate cancer: influence of V150 and V200 parameters.

Duchesne GM, Das R, Toye W, See A. Duchesne GM, et al. Australas Radiol. 2002 Dec;46(4):384-9. doi: 10.1046/j.1440-1673.2002.01091.x. Australas Radiol. 2002. PMID: 12452909

5

Outcome, morbidity, and prognostic factors in post-prostatectomy radiotherapy: an Australian multicenter study.

Duchesne GM, Dowling C, Frydenberg M, Joseph D, Gogna NK, Neerhut G, Roberts S, Spry N, Turner S, Woo H. Duchesne GM, et al. Urology. 2003 Jan;61(1):179-83. doi: 10.1016/s0090-4295(02)02005-8. Urology. 2003. PMID: 12559292

6

Acceptability of short term neo-adjuvant androgen deprivation in patients with locally advanced prostate cancer.

Lamb DS, Denham JW, Mameghan H, Joseph D, Turner S, Matthews J, Franklin I, Atkinson C, North J, Poulsen M, Kovacev O, Robertson R, Francis L, Christie D, Spry NA, Tai KH, Wynne C, Duchesne G. Lamb DS, et al. Among authors: duchesne g. Radiother Oncol. 2003 Sep;68(3):255-67. doi: 10.1016/s0167-8140(03)00193-2. Radiother Oncol. 2003. PMID: 13129633 Clinical Trial.

7

Assessment of i-125 prostate implants by tumor bioeffect.

Haworth A, Ebert M, Waterhouse D, Joseph D, Duchesne G. Haworth A, et al. Among authors: duchesne g. Int J Radiat Oncol Biol Phys. 2004 Aug 1;59(5):1405-13. doi: 10.1016/j.ijrobp.2004.01.047. Int J Radiat Oncol Biol Phys. 2004. PMID: 15275726

8

Prostate implant evaluation using tumour control probability--the effect of input parameters.

Haworth A, Ebert M, Waterhouse D, Joseph D, Duchesne G. Haworth A, et al. Among authors: duchesne g. Phys Med Biol. 2004 Aug 21;49(16):3649-64. doi: 10.1088/0031-9155/49/16/012. Phys Med Biol. 2004. PMID: 15446795

9

Factors predicting for urinary morbidity following 125iodine transperineal prostate brachytherapy.

Williams SG, Millar JL, Duchesne GM, Dally MJ, Royce PL, Snow RM. Williams SG, et al. Among authors: duchesne gm. Radiother Oncol. 2004 Oct;73(1):33-8. doi: 10.1016/j.radonc.2004.07.026. Radiother Oncol. 2004. PMID: 15465143

10

Australian and New Zealand three-dimensional conformal radiation therapy consensus guidelines for prostate cancer.

Skala M, Berry M, Duchesne G, Gogna K, Tai KH, Turner S, Kneebone A, Rolfo A, Haworth A. Skala M, et al. Among authors: duchesne g. Australas Radiol. 2004 Dec;48(4):493-501. doi: 10.1111/j.1440-1673.2004.01354.x. Australas Radiol. 2004. PMID: 15601330 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

194 results

Search Page

Filters